We pooled data from the 100 parotid glands of 50 NPC patients that were treated with the TomoTherapy Hi-Art Treatment System (Accuray, Sunnyvale, CA). The patients were all initially diagnosed, histologically proven, and had a median age of 44 years (range: 11–80 years). Thirty of the 50 patients received platinum-based chemotherapy, and 20 others received only radiation therapy. Informed consent was obtained from all patients before receiving treatment. The main patient characteristics are summarized in Table 1 .
Tomotherapy hi art treatment system
Manufactured by Accuray
Sourced in United States
The TomoTherapy Hi-Art Treatment System is a radiation therapy device designed for cancer treatment. It uses a linear accelerator and a rotating computed tomography (CT) imaging system to deliver highly targeted radiation beams to the tumor while minimizing exposure to surrounding healthy tissue.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using tomotherapy hi art treatment system
1
Parotid Gland Radiation Therapy for NPC
2
Stereotactic Body Radiation Therapy for Prostate Cancer
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All patients underwent computed tomography (CT) scan in the treatment position (supine, arms crossed on forehead, and immobilized by thermoplastic mask). Contrast-enhanced axial images were obtained from the lower level of L3 to proximal femur at 3-mm intervals. A single-phase treatment plan was generated by the workstation of the TomoTherapy Hi-Art Treatment System (Accuray, Sunnyvalle, CA, USA) using plain CT images. Details of plan designing and dose-volume constraints for organs at risk (OARs) referred to our previous article.4 (link)
The dose-volume constraints for OARs in Group-1 were as follows: 1) femoral head V50 = 0%; 2) bladder and rectum V40 ≤ 40%; 3) bladder and rectum V65 ≤ 20%. In Group-2, the dose-volume constraints for OARs were: 1) femoral head V50 = 10%; 2) bladder and rectum V40 ≤ 40%; 3) bladder and rectum V60 ≤ 20%. BED3 in both groups reached 132.7 Gy (α/β = 3 Gy). The plan required that the prescription dose covers at least 95% of the PTV. A field width of 2.5 cm was used for all patients.
The target volumes and OARs were contoured by the same group of radiation oncologists. Physicists in the same group designed and verified the treatment plans. The plans were delivered after having been approved by senior radiation oncologists.
The dose-volume constraints for OARs in Group-1 were as follows: 1) femoral head V50 = 0%; 2) bladder and rectum V40 ≤ 40%; 3) bladder and rectum V65 ≤ 20%. In Group-2, the dose-volume constraints for OARs were: 1) femoral head V50 = 10%; 2) bladder and rectum V40 ≤ 40%; 3) bladder and rectum V60 ≤ 20%. BED3 in both groups reached 132.7 Gy (α/β = 3 Gy). The plan required that the prescription dose covers at least 95% of the PTV. A field width of 2.5 cm was used for all patients.
The target volumes and OARs were contoured by the same group of radiation oncologists. Physicists in the same group designed and verified the treatment plans. The plans were delivered after having been approved by senior radiation oncologists.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!